In humans uric acid (UA) is the end product of degradation of purines. The handling of UA by the renal system is a complex process which is not fully understood. To date, several urate transporters in the renal proximal tubule have been identified. Among them, urate transporter 1 (URAT1) and a glucose transporter 9 (GLUT9) are considered of greater importance, as potential targets for treatment of hyperuricemia and the potential associated cardio-metabolic risk. Therefore, the recognition of the metabolic pathway of UA and elucidation of occurrence of hyperuricemia may provide important insights about the relationship between UA, pre-hypertension (preHT) and the metabolic syndrome (MetS). We also review the available clinical studies in this field, including experimental studies dealing with the mechanisms of UA transport via different transporters, as well as current treatment options for hyperuricemia in patients with MetS, preHT or cardiovascular risk factors.

Rizzo, M., Obradovic, M., Labudovic-Borovic, M., Nikolic, D., Montalto, G., Rizvi, A.A., et al. (2013). Uric acid metabolism in pre-hypertension and the metabolic syndrome. CURRENT VASCULAR PHARMACOLOGY, 00(4), 572-585 [10.2174/1570161111999131205160756].

Uric acid metabolism in pre-hypertension and the metabolic syndrome

RIZZO, Manfredi;NIKOLIC, Dragana;MONTALTO, Giuseppe;
2013

Abstract

In humans uric acid (UA) is the end product of degradation of purines. The handling of UA by the renal system is a complex process which is not fully understood. To date, several urate transporters in the renal proximal tubule have been identified. Among them, urate transporter 1 (URAT1) and a glucose transporter 9 (GLUT9) are considered of greater importance, as potential targets for treatment of hyperuricemia and the potential associated cardio-metabolic risk. Therefore, the recognition of the metabolic pathway of UA and elucidation of occurrence of hyperuricemia may provide important insights about the relationship between UA, pre-hypertension (preHT) and the metabolic syndrome (MetS). We also review the available clinical studies in this field, including experimental studies dealing with the mechanisms of UA transport via different transporters, as well as current treatment options for hyperuricemia in patients with MetS, preHT or cardiovascular risk factors.
http://www.benthamdirect.org/pages/all_b_bypublication.php
Rizzo, M., Obradovic, M., Labudovic-Borovic, M., Nikolic, D., Montalto, G., Rizvi, A.A., et al. (2013). Uric acid metabolism in pre-hypertension and the metabolic syndrome. CURRENT VASCULAR PHARMACOLOGY, 00(4), 572-585 [10.2174/1570161111999131205160756].
File in questo prodotto:
File Dimensione Formato  
Uric acid.pdf

Solo gestori archvio

Dimensione 556.18 kB
Formato Adobe PDF
556.18 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/77626
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 17
social impact